Cancer-associated tumour markers CA 19-9 and CA-50 in patients with pancreatic cancer with special reference to the Lewis blood cell status
- PMID: 2390470
- PMCID: PMC1971719
- DOI: 10.1038/bjc.1990.241
Cancer-associated tumour markers CA 19-9 and CA-50 in patients with pancreatic cancer with special reference to the Lewis blood cell status
Abstract
Monoclonal antibodies 19-9 and C-50 were used to assay the cancer associated tumour antigens CA 19-9 and CA-50 in plasma from patients with confirmed pancreatic cancer, and related to the blood group and Lewis blood cell status. The plasma expressions of CA 19-9 or CA-50 were similar, including cases where the patients had Lewis phenotype Le (a-b-). However, analyses of both the tumour antigens could be used to differentiate the presence of cancer from its absence in Le (a-b-) individuals. The findings indicate that the targets for the monoclonal antibodies 19-9 and C-50 are similar. The practical implications of these findings are discussed.
Similar articles
-
Expression of blood group-related antigens in normal and malignant pancreatic tissue correlated with genotype of the patient defined by saliva glycoprotein.Cancer. 1993 Jan 1;71(1):71-81. doi: 10.1002/1097-0142(19930101)71:1<71::aid-cncr2820710113>3.0.co;2-4. Cancer. 1993. PMID: 8416729
-
Expression of blood group-related antigens ABH, Lewis A, Lewis B, Lewis X, Lewis Y, and CA 19-9 in pancreatic cancer cells in comparison with the patient's blood group type.Cancer Res. 1988 Oct 1;48(19):5422-6. Cancer Res. 1988. PMID: 3166398
-
Comparative study on the expression of the blood group antigens Le(a), Le(b), Le(x), Le(y) and the carbohydrate antigens CA19-9 and CA-50 in chronic pancreatitis and pancreatic carcinoma.Acta Histochem Suppl. 1990;40:143-6. Acta Histochem Suppl. 1990. PMID: 2091042 No abstract available.
-
Role of tumour markers, cytogenetics.Ann Oncol. 1999;10 Suppl 4:145-9. Ann Oncol. 1999. PMID: 10436809 Review.
-
[2-->6 Sialyl Le(a) antigen].Nihon Rinsho. 2005 Aug;63 Suppl 8:663-8. Nihon Rinsho. 2005. PMID: 16149606 Review. Japanese. No abstract available.
Cited by
-
Case Report: Overcoming challenges in pancreatic cancer with liver metastases: a personalized therapeutic odyssey of TACE, ablation, and immunotherapy.Front Immunol. 2023 Oct 11;14:1275782. doi: 10.3389/fimmu.2023.1275782. eCollection 2023. Front Immunol. 2023. PMID: 37885893 Free PMC article.
-
Monoclonal antibody 16D10 to the C-terminal domain of the feto-acinar pancreatic protein binds to membrane of human pancreatic tumoral SOJ-6 cells and inhibits the growth of tumor xenografts.Neoplasia. 2004 Nov-Dec;6(6):713-24. doi: 10.1593/neo.04298. Neoplasia. 2004. PMID: 15720797 Free PMC article.
-
Evaluation of CEA, CA 19-9, CA-50, CA-195, and TATI with special reference to pancreatic disorders.Int J Pancreatol. 1991 May;8(4):333-44. doi: 10.1007/BF02952725. Int J Pancreatol. 1991. PMID: 1791319
-
Identification of tumour antigens by serological analysis of cDNA expression cloning.Cancer Immunol Immunother. 2004 Mar;53(3):139-43. doi: 10.1007/s00262-003-0471-y. Epub 2004 Jan 13. Cancer Immunol Immunother. 2004. PMID: 14722670 Free PMC article. Review.
-
Advances in biomarker research for pancreatic cancer.Curr Pharm Des. 2012;18(17):2439-51. doi: 10.2174/13816128112092439. Curr Pharm Des. 2012. PMID: 22372502 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical